US-ah mRNA Technology hmangin HIV vaccine enchhinna kalpui ṭan

Messenger RNA technology hmanga mihring taksaa HIV vaccine enchhin mek a ni tih biotech firm Moderna leh International AIDS Vaccine Initiative chuan Ningani khan an puang.

Phase 1 trial hi United States-a puitling natna benvawn nei lo leh HIV kai lo mi 56-ah neih a ni.

Kum 40 vel zet zirchianna neih a nih hnuah, doctor te chuan AIDS natna laka min veng thei tur vaccine an la siamchhuak thei lo a, he natna hi khawvel pumah kumtinin mi sang telin an thihpui ziah a ni.

mRNA technology hmanga hun reilote chhunga Covid-19 vaccine an hmuhchhuah theih avangin, HIV vaccine siamna tur atan pawh beiseina an neih phah a ni. Vaccine hian antibody chi khat "broadly neutralizing antibodies," emaw bnAbs emaw chu pechhuakin, tunhnaia HIV variant tam tak lakah a veng thei dawn a ni, an ti. He vaccine hian taksaah natna dotu chi khat B lymphocytes pe chhuak turin kan taksa chu a zirtir dawn tih an sawi.

Zirchiannaah hian participant-te chu immunogen hmanga chiu an nih hnuah, immunogen booster pek leh an ni. Heng substance te hi mRNA technology hmanga pek an ni dawn a ni.Immunogens hi IAVI leh Scripps Research Institute bakah Bill & Melinda Gates Foundation, US National Institute of Allergy and Infectious Diseases leh Moderna ṭangkawpin an siam a ni.

Nikum khan Immunogen trial vawi khatna hi mRNA technology tel loa enchhin a lo ni tawh a ni. Zirchiannaa tel mipuite chungah an beisei ang tak result an hmuh thu an sawi. "mRNA vaccine kan siamchhuah theih dan thlirin, vaccine design leh testing awlsam leh zangkhai zawkah a siam thei a ni," tiin Moderna-IAVI chuan thuchhuah inṭawm chuan an sawi.

"HIV vaccine siamchhuak tur hian hun rei tak kan bei tawh a, immunogens siamna tur hmanrua leh kailawn thar kan neih avang hian hun rei lote chhungin kan mamawh em em HIV vaccine siamchhuahna tura kawng pawimawh tak a ni thei dawn a ni," tiin IAVI CEO Mark Feinberg chuan a sawi a ni.